Iovance Biotherapeutics Inc
NASDAQ:IOVA

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Watchlist
Price: 8.55 USD 3.76% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Iovance Biotherapeutics Inc?
Write Note

Intrinsic Value

IOVA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IOVA stock under the Base Case scenario is 13.26 USD. Compared to the current market price of 8.55 USD, Iovance Biotherapeutics Inc is Undervalued by 36%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IOVA Intrinsic Value
13.26 USD
Undervaluation 36%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Iovance Biotherapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IOVA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IOVA?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Iovance Biotherapeutics Inc

Provide an overview of the primary business activities
of Iovance Biotherapeutics Inc.

What unique competitive advantages
does Iovance Biotherapeutics Inc hold over its rivals?

What risks and challenges
does Iovance Biotherapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Iovance Biotherapeutics Inc recently?

Summarize the latest earnings call
of Iovance Biotherapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Iovance Biotherapeutics Inc.

Provide P/S
for Iovance Biotherapeutics Inc.

Provide P/E
for Iovance Biotherapeutics Inc.

Provide P/OCF
for Iovance Biotherapeutics Inc.

Provide P/FCFE
for Iovance Biotherapeutics Inc.

Provide P/B
for Iovance Biotherapeutics Inc.

Provide EV/S
for Iovance Biotherapeutics Inc.

Provide EV/GP
for Iovance Biotherapeutics Inc.

Provide EV/EBITDA
for Iovance Biotherapeutics Inc.

Provide EV/EBIT
for Iovance Biotherapeutics Inc.

Provide EV/OCF
for Iovance Biotherapeutics Inc.

Provide EV/FCFF
for Iovance Biotherapeutics Inc.

Provide EV/IC
for Iovance Biotherapeutics Inc.

Show me price targets
for Iovance Biotherapeutics Inc made by professional analysts.

What are the Revenue projections
for Iovance Biotherapeutics Inc?

How accurate were the past Revenue estimates
for Iovance Biotherapeutics Inc?

What are the Net Income projections
for Iovance Biotherapeutics Inc?

How accurate were the past Net Income estimates
for Iovance Biotherapeutics Inc?

What are the EPS projections
for Iovance Biotherapeutics Inc?

How accurate were the past EPS estimates
for Iovance Biotherapeutics Inc?

What are the EBIT projections
for Iovance Biotherapeutics Inc?

How accurate were the past EBIT estimates
for Iovance Biotherapeutics Inc?

Compare the revenue forecasts
for Iovance Biotherapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Iovance Biotherapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Iovance Biotherapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Iovance Biotherapeutics Inc compared to its peers.

Compare the P/E ratios
of Iovance Biotherapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Iovance Biotherapeutics Inc with its peers.

Analyze the financial leverage
of Iovance Biotherapeutics Inc compared to its main competitors.

Show all profitability ratios
for Iovance Biotherapeutics Inc.

Provide ROE
for Iovance Biotherapeutics Inc.

Provide ROA
for Iovance Biotherapeutics Inc.

Provide ROIC
for Iovance Biotherapeutics Inc.

Provide ROCE
for Iovance Biotherapeutics Inc.

Provide Gross Margin
for Iovance Biotherapeutics Inc.

Provide Operating Margin
for Iovance Biotherapeutics Inc.

Provide Net Margin
for Iovance Biotherapeutics Inc.

Provide FCF Margin
for Iovance Biotherapeutics Inc.

Show all solvency ratios
for Iovance Biotherapeutics Inc.

Provide D/E Ratio
for Iovance Biotherapeutics Inc.

Provide D/A Ratio
for Iovance Biotherapeutics Inc.

Provide Interest Coverage Ratio
for Iovance Biotherapeutics Inc.

Provide Altman Z-Score Ratio
for Iovance Biotherapeutics Inc.

Provide Quick Ratio
for Iovance Biotherapeutics Inc.

Provide Current Ratio
for Iovance Biotherapeutics Inc.

Provide Cash Ratio
for Iovance Biotherapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Iovance Biotherapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Iovance Biotherapeutics Inc?

What is the current Free Cash Flow
of Iovance Biotherapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Iovance Biotherapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Iovance Biotherapeutics Inc

Current Assets 498.6m
Cash & Short-Term Investments 397.5m
Receivables 55.8m
Other Current Assets 45.3m
Non-Current Assets 492.5m
PP&E 179.3m
Intangibles 306.6m
Other Non-Current Assets 6.6m
Current Liabilities 118.1m
Accounts Payable 31.7m
Accrued Liabilities 86.4m
Non-Current Liabilities 99.6m
Long-Term Debt 1m
Other Non-Current Liabilities 98.6m
Efficiency

Earnings Waterfall
Iovance Biotherapeutics Inc

Revenue
90.9m USD
Cost of Revenue
-77.5m USD
Gross Profit
13.4m USD
Operating Expenses
-443.4m USD
Operating Income
-430m USD
Other Expenses
20m USD
Net Income
-410m USD

Free Cash Flow Analysis
Iovance Biotherapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

IOVA Profitability Score
Profitability Due Diligence

Iovance Biotherapeutics Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
Declining ROE
22/100
Profitability
Score

Iovance Biotherapeutics Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

IOVA Solvency Score
Solvency Due Diligence

Iovance Biotherapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
81/100
Solvency
Score

Iovance Biotherapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IOVA Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast IOVA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IOVA is 24.24 USD with a low forecast of 10.1 USD and a high forecast of 35.7 USD.

Lowest
Price Target
10.1 USD
18% Upside
Average
Price Target
24.24 USD
184% Upside
Highest
Price Target
35.7 USD
318% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IOVA?

Click here to dive deeper.

Dividends

Iovance Biotherapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for IOVA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IOVA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

IOVA News

Other Videos

Profile

Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.6B USD

Dividend Yield

0%

Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. The company is headquartered in San Carlos, California and currently employs 319 full-time employees. The company went IPO on 2008-06-20. The firm is focused on the development and commercialization of cell therapies as cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The company has developed a new, shorter manufacturing process for tumor infiltrating lymphocyte (TIL) known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and metastatic cervical cancer, as well as LN-145 for metastatic non-small cell lung cancer (NSCLC). In addition, the Company is investigating the combinations of TIL therapy with immune checkpoint inhibitors (ICIs) in metastatic melanoma, cervical cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). The company is investigating peripheral blood lymphocyte (PBL) therapy for patients with refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Contact

CALIFORNIA
San Carlos
999 Skyway Rd Ste 150
+16502607120.0
www.iovance.com

IPO

2008-06-20

Employees

319

Officers

Interim CEO, President, General Counsel, Corporate Secretary & Director
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
CFO, Principal Accounting Officer & Treasurer
Mr. Jean-Marc Bellemin M.B.A.
Chief Operating Officer
Dr. Igor P. Bilinsky Ph.D.
Chief Medical Officer
Dr. Friedrich Graf Finckenstein M.D.
Vice President of Investor Relations & Public Relations
Ms. Sara Pellegrino
Executive Vice President of Human Resources
Ms. Tracy Winton
Show More
Chief Business Officer
Mr. Howard B. Johnson M.B.A.
Executive VP of Regulatory Strategy & Translational Medicine
Dr. Raj K. Puri M.D., Ph.D.
Senior VP & Head of Digital and Information Technology
Mr. Brian Shew M.B.A.
Executive Vice President of Quality
Mr. Kevin Smyth
Show Less

See Also

Discover More
What is the Intrinsic Value of one IOVA stock?

The intrinsic value of one IOVA stock under the Base Case scenario is 13.26 USD.

Is IOVA stock undervalued or overvalued?

Compared to the current market price of 8.55 USD, Iovance Biotherapeutics Inc is Undervalued by 36%.

Back to Top